LTS Therapy Systems Importer Registration Application for Schedule I Controlled Substance
Summary
DEA published notice that LTS Therapy Systems, LLC (West Saint Paul, Minnesota) applied on March 6, 2026 to be registered as an importer of Dimethyltryptamine (Drug code 7435, Schedule I). The company plans to import the controlled substance as bulk API for internal research, development, and analytical purposes only. Registered bulk manufacturers and applicants may submit electronic comments or written hearing requests on or before May 18, 2026.
What changed
DEA published a notice of application by LTS Therapy Systems, LLC to be registered as an importer of Dimethyltryptamine (Drug code 7435, Schedule I) as a bulk active pharmaceutical ingredient (API) for internal research, development, and analytical purposes only. The registration would not authorize import of FDA-approved or non-approved finished dosage forms for commercial sale. Registered bulk manufacturers of the affected controlled substance class and applicants may submit electronic comments or written hearing requests to DEA on or before May 18, 2026.
Affected parties, including existing registered bulk manufacturers of Schedule I controlled substances and other applicants, may file comments or hearing requests by the May 18, 2026 deadline. Approval of the importer registration will only occur when the registrant's business activity is consistent with authorization under 21 U.S.C. 952(a)(2), and authorization will not extend to commercial sale of finished dosage forms.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
ACTION:
Notice of application.
SUMMARY:
LTS Therapy Systems, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer
to
SUPPLEMENTARY INFORMATION
listed below for further drug information.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on
or objections to the issuance of the proposed registration on or before May 18, 2026. Such persons may also file a written
request for a hearing on the application on or before May 18, 2026.
ADDRESSES:
The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file
for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive
a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit
the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.34(a), this is notice that on March 6, 2026, LTS Therapy Systems, LLC, 1685 Marthaler Lane,
West Saint Paul, Minnesota 55118-3517, applied to be registered as an importer of the following basic class(es) of controlled
substance(s):
| Controlled substance | Drug code | Schedule |
|---|---|---|
| Dimethyltryptamine | 7435 | I |
The company plans to import the above controlled substance as bulk API for internal research, development, and analytical
purposes only. No other activity for this drug code is authorized for this registration.
Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved
finished dosage forms for commercial sale.
Thomas Prevoznik, Deputy Assistant Administrator. [FR Doc. 2026-07558 Filed 4-16-26; 8:45 am] BILLING CODE P
Download File
CFR references
Mentioned entities
Citations
Parties
Related changes
Get daily alerts for Regulations.gov Final Notices
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from DEA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regulations.gov Final Notices publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.